XML 31 R24.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Collaboration and Other Agreements, Les Laboratoires Servier (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2012 USD ($) | Nov. 30, 2011 USD ($) | Sep. 30, 2015 USD ($) | Sep. 30, 2014 USD ($) | Sep. 30, 2015 USD ($) Molecule | Sep. 30, 2014 USD ($) | Dec. 31, 2014 USD ($)
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Deferred revenue included in current liabilities |  |  | $ 7,163,000 |  | $ 7,163,000 |  | $ 14,248,000
Deferred revenue included in long-term liabilities |  |  | 11,889,000 |  | $ 11,889,000 |  | 16,472,000
Servier [Member] | Servier MGA271 [Member] |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Agreement beginning date |  |  |  |  | November 2011 |  |
Non-refundable upfront payment |  | $ 20,000,000 |  |  |  |  |
Additional Potential License Fees Under Agreement |  |  | 30,000,000 |  | $ 30,000,000 |  |
Additional Potential Clinical Milestone Payments Under Agreement |  |  | 47,000,000 |  | 47,000,000 |  |
Additional Potential Regulatory Milestone Payments Under Agreement |  |  | 140,000,000 |  | 140,000,000 |  |
Additional Potential Sales Milestone Payments Under Agreement |  |  | 208,000,000 |  | $ 208,000,000 |  |
Original period of development |  |  |  |  | 27 months |  |
Expected period of development |  |  |  |  | 42 months |  |
Recognized revenue under agreement |  |  | 14,000 | $ 200,000 | $ 100,000 | $ 600,000 |
Deferred revenue |  |  |  |  |  |  | 100,000
Servier [Member] | Servier DART [Member] |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |
Agreement beginning date |  |  |  |  | September 2012 |  |
Non-refundable upfront payment | $ 20,000,000 |  |  |  |  |  |
Additional Potential License Fees Under Agreement |  |  | 65,000,000 |  | $ 65,000,000 |  |
Additional Potential Clinical Milestone Payments Under Agreement |  |  | 98,000,000 |  | 98,000,000 |  |
Additional Potential Regulatory Milestone Payments Under Agreement |  |  | 300,000,000 |  | 300,000,000 |  |
Additional Potential Sales Milestone Payments Under Agreement |  |  | 630,000,000 |  | $ 630,000,000 |  |
Original period of development |  |  |  |  | 29 months |  |
Expected period of development |  |  |  |  | 75 months |  |
Recognized revenue under agreement |  |  | 800,000 | 5,800,000 | $ 2,600,000 | 15,900,000 |
Deferred revenue |  |  | 15,200,000 |  | 15,200,000 |  | 17,700,000
Additional Potential Milestone Payments per IND filing |  |  | 5,000,000 |  | 5,000,000 |  |
License option fees received |  |  |  |  |  | 15,000,000 |
Clinical milestone payments received under agreement |  |  | 0 | 5,000,000 | 0 | 10,000,000 |
Offset to research and development costs under collaboration arrangement |  |  | 0 | $ 0 | $ 500,000 | $ 0 |
Expected development period |  |  |  |  | 82 months |  |
Review period |  |  |  |  | 30 days |  |
Deferred revenue included in current liabilities |  |  | 3,300,000 |  | $ 3,300,000 |  | 3,300,000
Deferred revenue included in long-term liabilities |  |  | $ 11,900,000 |  | $ 11,900,000 |  | $ 14,400,000
Number Of Molecules To Be Developed And Commercialized Under Agreement | Molecule |  |  |  |  | 3 |  |

X
- Definition Additional clinical milestone payment received under agreement. + References No definition available. + Details
Name: | mgnx_AdditionalClinicalMilestonePaymentReceivedUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate potential clinical milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential license grant fees available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialLicenseFeesUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional potential milestone payments receivable upon new drug application acceptance. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential sales milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Date on which the Company entered into agreement. + References No definition available. + Details
Name: | mgnx_CollaborationAndOtherAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to collaboration arrangement offset to research and development costs. + References No definition available. + Details
Name: | mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement expected development period. + References No definition available. + Details
Name: | mgnx_CollaborativeArrangementExpectedDevelopmentPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial fee received from collaboration or license agreement. + References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of molecules to be developed and commercialized as per collaboration. + References No definition available. + Details
Name: | mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Original recognition period for development. + References No definition available. + Details
Name: | mgnx_OriginalPeriodOfDevelopment
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to review period by regulatory authority. + References No definition available. + Details
Name: | mgnx_ReviewPeriodByRegulatoryAuthority
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to upfront payment recognition period. + References No definition available. + Details
Name: | mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgnx_ServierMGA271Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |